Please login to the form below
Content Strategy for pharma: Maturing your approach in 2016
In this article, Consultant Adwoa Baah and Content Marketing Manager Liz Inskip take us through three things pharma can do to improve content strategy maturity within their organisations in 2016.
Content isn’t new.
It’s something that the industry has been talking about for several years now,
and the phrase ‘Content is King’ has been around for what feels like aeons.
However, the way that many pharma and healthcare brands think about content
strategy – the creation, management, storage, and governance of content –
hasn’t matured in quite the same way as their multichannel
marketing strategy has. And with multichannel marketing
has come a common adverse event – channel stuffing to get around a lack of
relevant content.
In this article, Consultant Adwoa Baah and Content Marketing Manager Liz Inskip take us through three things pharma can do to improve content strategy maturity within their organisations in 2016.
![]()
In this article, Consultant Adwoa Baah and Content Marketing Manager Liz Inskip take us through three things pharma can do to improve content strategy maturity within their organisations in 2016.
1. Define what content strategy is in your company
“Content Strategy” can take many different forms, so what’s important first and foremost is that you take a look at how your brands currently work with content. If yours is like most companies, there won’t be an organisation-wide process in place. It will be down to individual brand teams to decide how they create, distribute, manage, and govern their content. This might work for some teams, but ultimately, you’ll want to ensure that there are best practice guidelines that teams can turn to.Download the full article from Blue Latitude Health here
Company Details
Blue Latitude Health
+44 203 328 1840
Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom
Latest content on this profile
- What does the future hold for Medical Affairs?
- Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
- Unpacking rare diseases in the first edition of Delta magazine
- Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health
- Great creative is effective creative. And effective creative is affective creative
- Our creative approach at Fishawack Health is Affective Creativity. Creative crafted to make deep, motivating connections with our target audience. We tap into psychology and combine that with creative craft and expertise and to deliver powerful, engaging work on a conscious as well as a subconscious level.
Blue Latitude Health
